Drug Profile
LM 002
Alternative Names: LM-002Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals; Livzon Pharmaceuticals
- Class Infertility therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Infertility
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Infertility in China
- 12 Jul 2019 LM 002 is still in preclinical trials for Infertility in China (Alphamab pipeline, July 2019)
- 07 May 2015 Preclinical trials in Infertility in China (unspecified route)